Physician profile
Michael Eaton
NPI 1508065913
$11,341.44
in general payments reported to CMS, 2019-2025
68 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $724 · 2021: $1,008 · 2022: $1,711 · 2023: $3,430 · 2024: $1,378 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,794 · Travel and Lodging: $937 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,793.82 |
| Travel and Lodging | $936.69 |
| Education | $238.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,583.11 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,243.88 | 2019-2025 | Kisqali, Piqray |
| Elekta, INC. | $845.55 | 2019-2025 | Elekta Medical Linear Accelerator |
| Siemens Medical Solutions USA, INC. | $660.98 | 2019-2025 | Truebeam, Varian Ethos Treatment Planning, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Astrazeneca Pharmaceuticals LP | $545.34 | 2019-2025 | Lynparza, Enhertu |
| Astellas Pharma US INC | $488.29 | 2020-2025 | Padcev, Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $455.36 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $412.05 | 2019-2025 | |
| Daiichi Sankyo INC. | $364.36 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Exelixis INC. | $361.36 | 2019-2024 | Cabometyx |
| Genzyme Corporation | $331.42 | 2019-2025 | |
| Janssen Biotech, INC. | $323.15 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Eisai INC. | $300.17 | 2019-2024 | |
| Seagen INC. | $270.21 | 2019-2025 | Padcev, Tukysa, Adcetris |
| Novocure INC. | $220.75 | 2020-2023 | Optune |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.